Figure 2.

Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire dimensions, assessed prior to treatment and after 2 weeks of treatment with esomeprazole, in German patients with symptoms suggestive of gastro-oesophageal reflux disease; p < 0.0001 for all changes vs. pretreatment (baseline) (23). Reprinted from Kulig M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease – an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767–76, with permission from Blackwell Publishing. RE, reflux oesophagitis (patients received esomeprazole 40 mg/day for 4 weeks in total); NERD, non-erosive reflux disease (patients received esomeprazole 20 mg/day for 2 weeks)